STING1 and cancer: Together, the integration of Fe2+-driven ferroptosis and STING agonist-triggered immunotherapy in OMV/SaFeFA represents a potent strategy to synergize oxidative damage and immune activation, offering a biocompatible and effective approach for refractory cancer therapy [154].